Apollomics Shares Are Trading Lower After the Company Announced Its Phase 3 Bridging Trial of Uproleselan in China Did Not Demonstrate a Favorable Benefit.

BenzingaDec 20 08:44 ET

Apollomics Shares Down in Premarket After Leukemia Drug Misses Phase-3 Targets

WSJDec 20 08:30 ET

Express News | Apollomics Inc - Serious Adverse Events 43% in Uproleselan Arm Vs 39% in Control

ReutersDec 20 08:03 ET

Express News | Apollomics Inc: Trial Did Not Demonstrate Favorable Benefit for Uproleselan

ReutersDec 20 08:03 ET

Express News | Apollomics Announces Top-Line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients With Relapsed or Refractory Acute Myeloid Leukemia

ReutersDec 20 08:00 ET

Apollomics Regains Compliance With Nasdaq's Minimum Bid Price Requirement

BenzingaDec 10 16:15 ET